ResultsIQ › Latest results › Poly Medicure Limited
Poly Medicure Limited Q2 FY27 earnings call summary
NSE: POLYMED · BSE: 531768
Earnings call of 5 Nov 2026, summarised by AI from the filing.
European business grew close to 40% organically in Q2 on customer additions and inventory normalization.
Key takeaways
- Europe driver European business grew close to 40% organically in Q2 on customer additions and inventory normalization.
- ROW risk ROW revenue fell 7% in Q2 on West Asia conflict, container shortage and higher freight costs.
Poly Medicure Limited Q2 FY27 results
As filed: Revenue ₹581 cr (+31% year on year), EBITDA ₹138 cr (+20% year on year), PAT ₹95.1 cr (+3% year on year), EBITDA margin 23.7% (−220 bps).
The Q2 FY27 score, against the company's own trend, is for premium members.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹525 cr (+30% year on year), EBITDA ₹125 cr (+18% year on year), PAT ₹85.3 cr (−8% year on year), EBITDA margin 23.8% (−249 bps). Score 49 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was above it; profit growth was below it. EBITDA margin fell 249 bps year on year. Other income 29% of PBT. Share price after the results: −0.4% in 28 days (Nifty 500: −2.0%).
- Q4 FY26: Revenue ₹535 cr (+21% year on year), EBITDA ₹110 cr (−8% year on year), PAT ₹65.0 cr (−29% year on year), EBITDA margin 20.7% (−656 bps). Score 32 of 100, Below trend. Revenue growth was above the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 656 bps year on year. Profit fell 8% from last quarter. Revenue rose ₹93.5 cr on a year ago, more than the ₹63.0 cr it added the year before. Share price after the results: +6.7% in 30 days (Nifty 500: +0.9%).
- Q3 FY26: Revenue ₹494 cr (+16% year on year), EBITDA ₹111 cr (−3% year on year), PAT ₹70.8 cr (−17% year on year), EBITDA margin 22.5% (−460 bps). Score 14 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 460 bps year on year. Other income 27% of PBT. Profit fell 23% from last quarter. Profit rose ₹-14.2 cr on a year ago, against ₹20.0 cr the year before. Share price after the results: −10.6% in 29 days (Nifty 500: −4.5%).
- Q2 FY26: Revenue ₹444 cr (+6% year on year), EBITDA ₹115 cr (0% year on year), PAT ₹92.0 cr (+6% year on year), EBITDA margin 25.9% (−148 bps). Score 9 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 148 bps year on year. Other income 28% of PBT. Revenue rose ₹24.0 cr on a year ago, against ₹83.0 cr the year before. Share price after the results: −1.9% in 30 days (Nifty 500: 0.0%).
- Q1 FY26: Revenue ₹403 cr (+5% year on year), EBITDA ₹106 cr (+2% year on year), PAT ₹93.0 cr (+26% year on year), EBITDA margin 26.3% (−71 bps). Score 27 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was in line with it. EBITDA margin fell 71 bps year on year. Other income 34% of PBT. Revenue fell 9% from last quarter. Revenue rose ₹18.0 cr on a year ago, against ₹64.0 cr the year before. Share price after the results: +5.5% in 28 days (Nifty 500: +0.6%).
- Q4 FY25: Revenue ₹441 cr (+17% year on year), EBITDA ₹120 cr (+25% year on year), PAT ₹92.0 cr (+35% year on year), EBITDA margin 27.2% (+181 bps). Score 70 of 100, Above trend. Revenue growth was well below the company's own trend; EBITDA growth was in line with it; profit growth was above it. EBITDA margin rose 181 bps year on year. Revenue rose ₹63.0 cr on a year ago, against ₹71.0 cr the year before. Share price after the results: −19.6% in 30 days (Nifty 500: +4.5%).
- Q3 FY25: Revenue ₹424 cr (+25% year on year), EBITDA ₹115 cr (+29% year on year), PAT ₹85.0 cr (+31% year on year), EBITDA margin 27.1% (+95 bps). Score 69 of 100, Above trend. Revenue, EBITDA and profit growth were above the company's own trend. EBITDA margin rose 95 bps year on year. Revenue rose ₹84.0 cr on a year ago, more than the ₹55.0 cr it added the year before.
Past price moves after results do not indicate future moves. Not a recommendation.
Poly Medicure Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Earnings call (5 Nov 2026), Results deck (5 Nov 2026)
- Q1 FY27: Results deck (7 Aug 2026)
- Q4 FY26: Earnings call (25 May 2026), Results deck (25 May 2026), Results deck (25 May 2026)
- Q3 FY26: Earnings call (6 Feb 2026), Results deck (5 Feb 2026)
- Q2 FY26: Earnings call (10 Nov 2025), Results deck (8 Nov 2025)
- Q1 FY26: Earnings call (8 Aug 2025), Results deck (8 Aug 2025), Results press release (8 Aug 2025)
- Q4 FY25: Earnings call (7 May 2025), Results deck (6 May 2025), Results press release (6 May 2025)
- Other events: Strategy deck (7 Mar 2026), Special call (25 Sep 2025), Strategy deck (25 Sep 2025), Strategy deck (24 Sep 2025), Special call (4 Sep 2025), Strategy deck (3 Sep 2025)
Figures from the company's filings with NSE and BSE. Not investment advice.